Coronavirus

Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License

ABINGDON, United Kingdom, June 18, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical-stage biotechnology company…

6 months ago

Replimune Announces $100 Million Private Placement Financing

- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors…

7 months ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

7 months ago

Hospital PMI® at 58.4%; May 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., June 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in May for the ninth consecutive month after…

7 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending…

7 months ago

ISM® Welcomes Steve Miller as Esteemed Chair of ISM Services Business Survey Committee

Anthony S. Nieves announces transition after distinguished leadership in chair role for over a decade TEMPE, Ariz., June 6, 2024…

7 months ago

Services PMI® at 53.8%; May 2024 Services ISM® Report On Business®

Business Activity Index at 61.2%; New Orders Index at 54.1%; Employment Index at 47.1%; Supplier Deliveries Index at 52.7% TEMPE,…

7 months ago

Theralase(R) Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

7 months ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More SHELTON, CT…

7 months ago

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an…

7 months ago